Newsroom | 1433 results

IRVINE, Calif.--(BUSINESS WIRE)--AIVITA Biomedical, Inc., a biotechnology company developing personalized vaccines for the prevention of infectious disease and treatment of cancer, today announced the appointment of renowned physician, epidemiologist, technologist, philanthropist, and author Larry Brilliant, M.D., M.P.H., to its board of directors. Dr. Brilliant brings globally recognized expertise in epidemiology, pandemic preparedness, and vaccine readiness that is especially relevant to AIVI...

NORTH BETHESDA, Md.--(BUSINESS WIRE)--The Foundation for the National Institutes of Health awards the 2026 Kovler Prize for Trust in Life Science Journalism to STAT's Helen Branswell....

FOSTER CITY, Calif.--(BUSINESS WIRE)--Please replace the release with the following corrected version due to a change in the "PRODUCT SALES SUMMARY" table, where the Odefsey sales in Europe have been updated to $58 million for the three months ended June 30, 2026 (instead of $28 million). The updated release reads: GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 10% Year-Over-Year to $7.6 billion Biktarvy Sales Increased 7% Year-Over-Yea...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2026 and raised its full-year 2026 Revenue guidance by $500 million at the midpoint while reaffirming guidance(2) for Adjusted(3) diluted EPS, which absorbs an impact of approximately $0.10 related to the Innovent Biologics, Inc. transaction. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: “Pfizer had another strong quarter, delivering on our financial commitments and adva...

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Commission (EC) has granted marketing authorization for the companies’ 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the Emergency Task Force (ETF) of the European Medic...

FLORHAM PARK, N.J.--(BUSINESS WIRE)--Shionogi Inc., a New Jersey-based subsidiary of Shionogi & Co., Ltd., (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, PhD; hereinafter “Shionogi”) announced U.S. availability of XOCOVA® (ensitrelvir), an oral antiviral, approved for post-exposure prophylaxis (PEP) of COVID‑19 in adults and adolescents 12 years of age and older following contact with an individual who has COVID-19.2 XOCOVA offers a new approach to help prevent COVID-1...

WASHINGTON--(BUSINESS WIRE)--The Independent Medical Alliance (IMA) today announced the publication of Volume 2, Issue 4 of the Journal of Independent Medicine, continuing to advance rigorous, conflict-free, double-blind peer-reviewed science.As the United States commemorates its 250th anniversary, the new issue features timely and notable medical research and observations, including:The Quiet Expansion of Death: Canada’s MAID Program and the Moral Fatigue of Modern MedicineTwo Hundred Fifty Yea...

THE WOODLANDS, Texas--(BUSINESS WIRE)--NPK International Inc. (NYSE: NPKI) (“NPK” or the “Company”) today announced that it will issue second quarter 2026 results after the U.S. markets close on Wednesday, July 29, 2026. A conference call will be held the following day on Thursday, July 30, 2026, at 9:30 a.m. ET to review the Company’s financial results and conduct a question-and-answer session. A webcast of the conference call and accompanying presentation materials will be available in the In...

WATERTOWN, Mass.--(BUSINESS WIRE)--Nocion Therapeutics, Inc., a biopharmaceutical company developing novel small molecule therapies that selectively silence activated sensory neurons, today announced that it will be presenting a poster at the European Respiratory Society (ERS) 2026 Cough Conference taking place from July 15-17, 2026, in London. The presentation details are as follows: Poster Title: The Nocion ASPIRE Study of Taplucainium in rCC: A Status Update Presenter: Matthew Frankel, M.D....

SAN JOSE, Calif.--(BUSINESS WIRE)--Visby Medical, the at-home diagnostics company, today announced U.S. Food and Drug Administration (FDA) clearance for the Visby Medical Flu and COVID-19 Test, the first multi-viral at-home PCR test. This marks Visby’s second over-the-counter PCR test and expands the company’s growing portfolio of rapid molecular diagnostics designed for home use. The clearance comes as demand for at-home testing continues to grow, particularly for respiratory infections like C...